

**Table S1. Population Pharmacokinetic Estimates for Emtricitabine (FTC)**

Parameter (units)	Final NONMEM Estimate	Median Bootstrap Estimate	Bootstrap 95% CI	%RSE
Ka (hr <sup>-1</sup> )*	0.6	0.6	--	--
CL/F (L/hr)	10.6	10.6	(9.39 – 11.9)	2.32%
V/F (L)	41.3	41.7	(33.0 – 49.4)	4.51%
Q/F (L/hr)	3.79	3.76	(3.04 – 4.58)	3.96%
V2/F (L)	43.1	43.0	(34.4 – 55.9)	5.19%
K24 (hr <sup>-1</sup> )	0.0133	0.0134	(0.00862 – 0.0175)	6.51%
K40 (hr <sup>-1</sup> )	0.0513	0.0521	(0.0342 – 0.0674)	6.47%
K25 (hr <sup>-1</sup> )	0.543	0.560	(0.410 – 0.739)	5.95%
K50 (hr <sup>-1</sup> )	0.109	0.140	(0.00180 – 0.215)	14.6%
K26 (hr <sup>-1</sup> )	0.0399	0.0188	(0.00100 – 0.127)	112%
K56 (hr <sup>-1</sup> )	0.0604	0.0345	(0.00100 – 0.159)	49.3%
K60 (hr <sup>-1</sup> )	1.80	1.25	(0.0263 – 4.83)	48.1%
ω on CL/F (%CV)	21.5%	20.8%	(14.8% - 28.8%)	15.3%
CL-V correlation	0.0283	0.0236	(-0.0113 – 0.0943)	46.7%
ω on V/F (%CV)	28.2%	26.6%	(13.6% - 46.8%)	101%
ω on K40 (%CV)	27.8%	26.3%	(15.1% - 36.6%)	16.5%
ω on K25 (%CV)	29.6%	28.3%	(1.92% - 40.3%)	20.5%
ω on K50 (%CV)	23.9%	26.9%	(0.0300% - 68.7%)	413%
ω on K60 (%CV)	78.1%	73.3%	(1.23% - 190%)	183%
σ on BP (%CV)	19.8%	19.6%	(17.1% - 21.7%)	4.56%
σ on PBMC (%CV)	36.2%	35.9%	(31.3% - 40.1%)	4.97%
σ on SP (%CV)	36.6%	36.1%	(28.9% - 42.7%)	7.62%
σ on SMC (%CV)	88.9%	82.2%	(68.4% - 95.0%)	6.32%

\* Fixed Parameter

95% CI - 95% Confidence Interval of bootstrap estimate

%RSE – Relative Standard Error in Percentage Terms

ω – Interindividual Variability

σ – Residual Variability

%CV – Coefficient of Variation in Percentage Terms